Fracture incidence and osteoporosis treatment in Parkinson’s disease: a population-based cohort study
Authors' conclusion
Despite elevated fracture risk, fewer than one in five individuals with PD received osteoporosis screening or treatment within a year of diagnosis.
Study context
- Population
- Individuals over 65 years with newly diagnosed Parkinson's disease, Ontario, Canada, January 2008–December 202339.9% female
- Participants
- 28,119 participants
- Outcome
- Fracture rates, osteoporosis medication use and BMD testing
- Follow-up
- Within 1 year of diagnosis
Methodological detailsadministrative data, Cox proportional hazard models adjusted for age, sex, Charlson comorbidity score, previous osteoporosis diagnosis, history of fragility fracture and corticosteroid use
- Administrative data
- Cox proportional hazard models adjusted for age, sex, Charlson comorbidity score, previous osteoporosis diagnosis, history of fragility fracture and corticosteroid use
Main finding
As reported in the abstract
Outcomes within 1 year of Parkinson's disease (PD) diagnosis
Fragility fracture
3.1%
Fragility fracture rate (per 100 person-years)
3.4
Prescription for osteoporosis medication
17.6%
Bone mineral density (BMD) test
9.8%
Observational data: associations, not effects.
Further findings
Outcomes by sex · 1 year
- Rates for all outcomes greater among females than males
Fracture rate predictors (adjusted analysis)
- Higher fracture rates in females, those aged ≥ 80 years, with prior fragility fractures, and higher comorbidity scores
Original publication
Fracture incidence and osteoporosis treatment in Parkinson’s disease: a population-based cohort study. Osteoporos Int. Published 10 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →